Cancer death rates in the United Kingdom have fallen to their lowest level ever recorded — a reduction of nearly 29% since the peak in 1989, according to the latest statistics from Cancer Research UK.
Between 2022 and 2024, around 247 people per 100,000 died from cancer each year in the UK. That compares to a peak of 355 per 100,000 in 1989 — a sustained, decades-long decline that reflects major advances in treatment, earlier diagnosis, and public health policy.
The Biggest Wins
The reductions have been dramatic across several major cancer types:
- Stomach cancer: deaths down 34% in the past decade
- Lung cancer: deaths down 22% in the past decade
- Ovarian cancer: deaths down 19%
- Breast cancer: deaths down 14%
- Prostate cancer: deaths down 11%
- Cervical cancer: deaths down 75% since the 1970s — the most dramatic improvement of all
The cervical cancer story is particularly striking. A combination of the NHS cervical screening programme — which detects pre-cancerous changes before cancer develops — and the HPV vaccine, introduced in 2008, has driven death rates down by three-quarters from their 1970s level.
What's Behind the Progress
Researchers point to several converging factors:
Screening programmes for breast, cervical, and colorectal cancers detect disease earlier, when treatment is more likely to succeed. Early-stage cancer is far more treatable than late-stage disease, and this alone has been responsible for significant survival improvements.
Targeted therapies and personalised medicine are increasingly common. Rather than one-size-fits-all chemotherapy, doctors can now tailor treatments to the biology of an individual patient's tumour — improving outcomes while reducing side effects.
Immunotherapy is advancing rapidly. Treatments that harness the immune system to fight cancer have transformed outcomes in melanoma, lung cancer, and haematological malignancies. Preventive vaccines for lung and ovarian cancer are now in development.
Public health policy — particularly smoking bans and anti-smoking campaigns — has driven major reductions in lung and other tobacco-related cancers.
Further Progress Within Reach
Researchers emphasise that the trend lines point toward even further improvement. The HPV vaccine cohort — children vaccinated from 2008 onwards — has barely entered the age range where HPV-linked cancers typically develop. As that cohort ages, cervical cancer cases are projected to fall to near-elimination in the UK.
Early cancer detection through blood tests, AI-assisted screening, and multi-cancer early detection panels is also advancing rapidly — with several clinical trials underway in the UK.
"The latest figures show what sustained investment in research, prevention and treatment can achieve," said Cancer Research UK. "Further progress is within reach."
Sources: Cancer Research UK · Positive News · NHS Digital (March 2026)
